Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based vaccines induce polyclonal antibody responses agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamilton, Erika, Blackwell, Kimberly, Hobeika, Amy C, Clay, Timothy M, Broadwater, Gloria, Ren, Xiu-Rong, Chen, Wei, Castro, Henry, Lehmann, Frederic, Spector, Neil, Wei, Junping, Osada, Takuya, Lyerly, H Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306270/
https://www.ncbi.nlm.nih.gov/pubmed/22325452
http://dx.doi.org/10.1186/1479-5876-10-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306270/
https://www.ncbi.nlm.nih.gov/pubmed/22325452
http://dx.doi.org/10.1186/1479-5876-10-28

Ejemplares similares